Welcome to our dedicated page for CeriBell news (Ticker: CBLL), a resource for investors and traders seeking the latest updates and insights on CeriBell stock.
CeriBell, Inc. (CBLL) delivers innovative neurological care solutions through its AI-powered EEG platform, transforming acute diagnosis in emergency and critical care settings. This page provides authorized news updates and official announcements about the company's medical technology developments.
Access timely updates on FDA clearances, clinical trial results, and strategic partnerships that demonstrate CeriBell's leadership in point-of-care diagnostics. Investors and healthcare professionals will find verified information about product innovations, peer-reviewed study outcomes, and operational milestones.
Our curated news feed includes regulatory filings, technology enhancements, and hospital adoption updates, offering comprehensive insights into CeriBell's market position. Bookmark this page for direct access to primary source materials about seizure detection systems and neurological monitoring advancements.
Ceribell has achieved FedRAMP High authorization for its AI-powered point-of-care EEG system, becoming one of only 51 companies in the U.S. to receive this elite cybersecurity designation. The company (Nasdaq: CBLL) can now expand its presence across federal healthcare facilities, including VA hospitals.
The authorization enables broader implementation of Ceribell's secure, cloud-based solution throughout federal healthcare agencies, facilitating faster diagnosis of non-convulsive seizures in veterans and high-risk patients. As of April 2025, fewer than 15% of FedRAMP Authorized systems meet the High security standard, and Ceribell is currently the only medical device company on the list.
The system, which received Authority to Operate (ATO) in 2024, is already in use at VA hospitals. This new authorization validates Ceribell's commitment to data security while enhancing patient care, positioning it among leading cloud and technology organizations meeting stringent federal cybersecurity standards.
Ceribell (Nasdaq: CBLL), a medical technology company specializing in neurological condition diagnostics, has scheduled its Q1 2025 financial results announcement for May 8, 2025, after market close. The company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results.
Investors can participate by dialing (800) 715-9871 (domestic) or (646) 307-1963 (international) with access code 7370458. A webcast will be available live and archived in the Investor Relations section of Ceribell's website.
Ceribell (Nasdaq: CBLL) has received FDA 510(k) clearance for its Clarity™ algorithm, becoming the first and only AI-powered point-of-care EEG system cleared to detect electrographic seizures in patients aged 1 year and older. The clearance was supported by EEG data from over 1,700 patients, marking the largest validation dataset ever used for FDA clearance of a seizure detection system.
The Clarity algorithm works with Ceribell's existing EEG headbands and enables rapid, bedside detection, diagnosis, and treatment of non-convulsive seizures in children experiencing neurological emergencies. Clinical guidelines recommend initiating EEG within 15-60 minutes of suspected continuous non-convulsive seizures, but children often face hours or days of waiting for assessment. This technology aims to address this critical gap by providing immediate bedside neurological assessment.
Ceribell (NASDAQ: CBLL) reported strong financial results for Q4 and full year 2024. Q4 revenue reached $18.5 million, up 41% year-over-year, while full-year revenue grew 45% to $65.4 million. The company maintained robust gross margins of 88% in Q4 and 87% for the full year.
Key highlights include reaching 529 total active accounts and treating over 200,000 patients. However, operating expenses increased 49% to $29.1 million in Q4, resulting in a net loss of $12.6 million ($0.40 per share). Full-year net loss was $40.5 million ($3.39 per share).
The company ended 2024 with $194.4 million in cash and cash equivalents. Looking ahead, Ceribell projects 2025 revenue between $81-85 million, representing 24-30% growth. The company also submitted a 510(k) application for its pediatric Clarity™ algorithm to the FDA.
Ceribell (Nasdaq: CBLL), a medical technology company specializing in neurological condition diagnosis and management, has announced its participation in the 45th Annual TD Cowen Healthcare Conference. The company's CEO and Co-founder, Jane Chao, Ph.D., along with CFO Scott Blumberg, will engage in a fireside chat scheduled for March 3, 2025, at 6:50 AM PST / 9:50 AM EST.
Interested parties can access both live and archived versions of the presentation through the Investor Relations section of Ceribell's website at investors.ceribell.com.
Ceribell (Nasdaq: CBLL), a medical technology company specializing in neurological condition diagnostics, has announced its upcoming financial results release. The company will disclose its fourth quarter and full year 2024 financial results after market close on February 25, 2025.
Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on the same day. Investors can participate by dialing (800) 715-9871 (domestic) or (646) 307-1963 (international) with access code 3782735. A webcast will be available live and archived in the Investor Relations section of Ceribell's website.
Ceribell (Nasdaq: CBLL), a medical technology company specializing in neurological diagnostics, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Jane Chao, Ph.D., CEO and Co-founder, will deliver a presentation on Monday, January 13, 2025, at 7:30 a.m. PST.
The presentation will be accessible through a live and archived webcast in the Investor Relations section of Ceribell's website. The company focuses on revolutionizing the diagnosis and management of serious neurological conditions through innovative medical technology solutions.
Ceribell (Nasdaq: CBLL) announced two key leadership appointments: Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing. Rodenbush brings 25+ years of HR experience and will lead the People & Culture team, having previously served as CPO at Meltwater. Price, with 25+ years in medical device industry experience, will focus on market development and penetration, coming from roles at VitalConnect, Medtronic, and Abbott. The appointments aim to support Ceribell's expansion of its AI-powered EEG neurodiagnostic system, addressing a significant market where up to one-third of ICU patients risk nonconvulsive seizures.
Ceribell (Nasdaq: CBLL), a medical technology company, reported third quarter 2024 financial results, showcasing a 48% increase in total revenue to $17.2 million compared to Q3 2023. Gross margin improved to 87% from 84% in the same period last year. The company ended the quarter with 504 active accounts and completed an IPO, raising $188 million in net proceeds. Product revenue rose by 52% to $13.3 million, while subscription revenue increased by 36% to $3.9 million. Despite these gains, operating expenses surged by 48% to $24.9 million, leading to a net loss of $10.4 million for the quarter, up from $7.1 million in Q3 2023. Cash and cash equivalents stood at $14.1 million as of September 30, 2024. Ceribell projects full-year 2024 revenue between $64.2 million and $64.7 million, marking a growth of 42% to 43% over the prior year.
Ceribell (NASDAQ: CBLL) has received Authority to Operate (ATO) from the Department of Veterans Affairs, enabling full deployment of its point-of-care EEG technology across VA hospitals. This authorization allows Ceribell to leverage VA Wi-Fi networks for remote access to EEG reports and data sharing between locations. The system, which has been used in certain VA facilities since 2018, aims to reduce costly ICU admissions and intra-facility patient transfers while supporting timely interventions for veterans, who face elevated risks of seizure disorders. The Ceribell System combines portable hardware with AI-powered algorithms for rapid diagnosis and continuous monitoring, and has been adopted by over 500 hospitals, serving more than 100,000 patients.
FAQ
What is the current stock price of CeriBell (CBLL)?
What is the market cap of CeriBell (CBLL)?
